Breakdown | ||||
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
189.27M | 174.02M | 165.54M | 75.58M | 71.49M | Gross Profit |
162.20M | 148.44M | 142.37M | 70.20M | 66.97M | EBIT |
19.73M | 19.23M | 18.13M | 13.24M | 19.21M | EBITDA |
54.26M | 51.60M | 47.54M | 18.48M | 24.06M | Net Income Common Stockholders |
11.70M | 9.23M | 9.41M | 12.90M | 16.84M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
34.59M | 78.54M | 47.16M | 235.62M | 47.85M | Total Assets |
543.65M | 576.98M | 568.79M | 311.60M | 115.76M | Total Debt |
40.15M | 86.69M | 113.08M | 1.15M | 2.02M | Net Debt |
5.56M | 8.15M | 65.93M | -234.47M | -45.83M | Total Liabilities |
215.06M | 249.13M | 235.77M | 51.32M | 47.36M | Stockholders Equity |
328.59M | 327.84M | 333.02M | 260.28M | 68.39M |
Cash Flow | Free Cash Flow | |||
24.91M | 83.20M | 12.93M | 13.21M | 10.96M | Operating Cash Flow |
41.86M | 98.75M | 26.96M | 23.54M | 20.67M | Investing Cash Flow |
-15.81M | -15.34M | -307.32M | -10.32M | -9.71M | Financing Cash Flow |
-70.00M | -53.28M | 91.90M | 174.55M | -10.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | £107.90M | 219.14 | 0.72% | 0.68% | -1.22% | -92.99% | |
61 Neutral | £640.83M | 68.82 | 3.56% | 1.57% | 3.99% | 22.16% | |
52 Neutral | £348.64M | ― | -27.75% | ― | -22.83% | -350.82% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
40 Underperform | £4.52M | ― | -28.11% | ― | -54.20% | 75.00% |
Craneware plc has announced a change in its major holdings as Aegon Ltd has acquired voting rights totaling 5.168% of Craneware’s shares. This acquisition indicates a strategic move by Aegon, potentially impacting Craneware’s shareholder dynamics and signaling confidence in the company’s market positioning.
Craneware plc announced a positive trading update for the first half of the fiscal year 2025, with revenues surpassing $100 million and adjusted EBITDA reaching approximately $30.3 million, driven by the success of its Trisus platform and strategic partnerships. The company also appointed Susan Nelson as a Non-Executive Director, bringing extensive experience in healthcare finance, and anticipates a stable demand environment in the US healthcare market, supported by strong cash reserves and reduced debt.